The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and Virbac SA are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak
Strong
Over the last 90 days Virbac SA has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable fundamental indicators, Virbac SA is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
Begin Period Cash Flow
179.6 M
Total Cashflows From Investing Activities
-51.2 M
Virbac
Virbac SA Relative Risk vs. Return Landscape
If you would invest 34,600 in Virbac SA on October 28, 2025 and sell it today you would earn a total of 0.00 from holding Virbac SA or generate 0.0% return on investment over 90 days. Virbac SA is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Virbac, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days.
Expected Return
Risk
Virbac SA Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Virbac SA for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Virbac SA can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Virbac SA generated a negative expected return over the last 90 days
About 50.0% of the company outstanding shares are owned by insiders
Virbac SA Fundamentals Growth
Virbac Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Virbac SA, and Virbac SA fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Virbac Pink Sheet performance.
By analyzing Virbac SA's fundamental ratios, stakeholders can gain valuable insights into Virbac SA's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Virbac SA has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Virbac SA has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Virbac SA manufactures and sells a range of products and services for companion and food-producing animals in France, Europe, Latin America, North America, the Asia Pacific, the Middle East, and Africa. Virbac SA was founded in 1968 and is headquartered in Carros, France. Virbac Sa operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 5120 people.
Things to note about Virbac SA performance evaluation
Checking the ongoing alerts about Virbac SA for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Virbac SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Virbac SA generated a negative expected return over the last 90 days
About 50.0% of the company outstanding shares are owned by insiders
Evaluating Virbac SA's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Virbac SA's pink sheet performance include:
Analyzing Virbac SA's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Virbac SA's stock is overvalued or undervalued compared to its peers.
Examining Virbac SA's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
Evaluating Virbac SA's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Virbac SA's management team can help you assess the Company's leadership.
Pay attention to analyst opinions and ratings of Virbac SA's pink sheet. These opinions can provide insight into Virbac SA's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Virbac SA's pink sheet performance is not an exact science, and many factors can impact Virbac SA's pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Complementary Tools for Virbac Pink Sheet analysis
When running Virbac SA's price analysis, check to measure Virbac SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virbac SA is operating at the current time. Most of Virbac SA's value examination focuses on studying past and present price action to predict the probability of Virbac SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virbac SA's price. Additionally, you may evaluate how the addition of Virbac SA to your portfolios can decrease your overall portfolio volatility.